ProVise Management Group LLC grew its stake in shares of Amrize Ltd (NYSE:AMRZ – Free Report) by 11.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after buying an additional 16,642 shares during the period. ProVise Management Group LLC’s holdings in Amrize were worth $6,145,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Moors & Cabot Inc. increased its holdings in Amrize by 46.0% in the 3rd quarter. Moors & Cabot Inc. now owns 29,600 shares of the company’s stock worth $1,107,000 after acquiring an additional 9,323 shares in the last quarter. Narwhal Capital Management raised its stake in Amrize by 23.8% during the 3rd quarter. Narwhal Capital Management now owns 81,263 shares of the company’s stock worth $3,038,000 after acquiring an additional 15,618 shares during the period. DMKC Advisory Services LLC lifted its holdings in Amrize by 11.3% during the third quarter. DMKC Advisory Services LLC now owns 75,488 shares of the company’s stock valued at $2,823,000 after purchasing an additional 7,656 shares in the last quarter. Pictet Asset Management Holding SA lifted its holdings in Amrize by 4.3% during the third quarter. Pictet Asset Management Holding SA now owns 6,126,150 shares of the company’s stock valued at $230,110,000 after purchasing an additional 253,512 shares in the last quarter. Finally, CenterBook Partners LP lifted its holdings in Amrize by 1,123.6% during the third quarter. CenterBook Partners LP now owns 101,408 shares of the company’s stock valued at $3,792,000 after purchasing an additional 93,120 shares in the last quarter.
Analyst Ratings Changes
A number of equities analysts have weighed in on the stock. Stephens dropped their price target on shares of Amrize from $65.00 to $54.00 and set an “overweight” rating for the company in a research report on Wednesday, August 12th. DA Davidson increased their price objective on shares of Amrize from $40.00 to $43.00 and gave the stock a “neutral” rating in a research note on Friday, October 30th. Berenberg Bank downgraded shares of Amrize from a “buy” rating to a “hold” rating and decreased their price objective for the company from $48.00 to $46.00 in a research report on Monday, November 9th. Barclays lowered their target price on shares of Amrize from $55.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, October 19th. Finally, UBS Group dropped their target price on shares of Amrize from $57.00 to $42.00 and set a “neutral” rating for the company in a report on Tuesday, September 22nd. Eight analysts have rated the stock with a Buy rating, seven have given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat.com, Amrize has a consensus rating of “Hold” and a consensus target price of $46.96.
Read Our Latest Report on Amrize
Insider Activity at Amrize
In related news, Director Jacques Sanche bought 4,150 shares of the stock in a transaction dated Wednesday, August 26th. The shares were purchased at an average price of $45.02 per share, with a total value of $186,833.00. Following the completion of the acquisition, the director owned 9,766 shares of the company’s stock, valued at $439,665.32. This represents a 73.90% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jan Jenisch bought 4,000 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was bought at an average cost of $42.50 per share, for a total transaction of $170,000.00. Following the acquisition, the chief executive officer directly owned 519,000 shares of the company’s stock, valued at approximately $22,057,500. This represents a 0.78% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 34,155 shares of company stock worth $1,461,276. Company insiders own 0.54% of the company’s stock.
Amrize Stock Down 0.1%
Shares of AMRZ opened at $40.85 on Monday. The business’s 50 day moving average is $39.33 and its 200 day moving average is $49.98. The company has a market capitalization of $22.59 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 1.60 and a beta of 0.03. Amrize Ltd has a 12-month low of $35.78 and a 12-month high of $65.94. The company has a current ratio of 1.07, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33.
Amrize (NYSE:AMRZ – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported $1.05 EPS for the quarter, hitting analysts’ consensus estimates of $1.05. Amrize had a return on equity of 10.02% and a net margin of 9.93%. The company had revenue of $3.77 billion for the quarter. During the same period in the prior year, the firm posted $0.98 earnings per share. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Research analysts expect that Amrize Ltd will post 2.30 earnings per share for the current fiscal year.
Amrize Announces Dividend
The business also recently disclosed a dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Tuesday, November 10th will be given a dividend of $0.11 per share. The ex-dividend date is Tuesday, November 10th. Amrize’s dividend payout ratio (DPR) is presently 4.98%.
Amrize Profile
Amrize is a North American building materials and construction solutions company serving customers across the United States and Canada. Its operations span the construction materials and building envelope markets. The company supplies cement, aggregates, ready-mix concrete and asphalt, as well as roofing and other building-envelope products and services. These materials and solutions support residential, commercial and infrastructure projects. Amrize became an independent publicly traded company in 2025 through the spin-off of Holcim’s North American business.
Featured Stories
- Five stocks we like better than Amrize
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding AMRZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amrize Ltd (NYSE:AMRZ – Free Report).
Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.
